BioCentury | Feb 4, 2013
Clinical News

Pirenzepine: Development discontinued

...tolerability of ACI-91 was rated as "good" in most patients. AC Immune in-licensed ACI-91 from ProteoSys...
...of crenezumab to treat AD are expected in 2014. AC Immune S.A. , Lausanne, Switzerland ProteoSys AG...
BioCentury | Aug 20, 2012
Emerging Company Profile

Mind-NRG: New neuroprotection

...that are involved in cognition and memory. In 2005, researchers at biomarker company ProteoSys AG (now ProteoSys...
...domain of the protein's beta-1 isoform - had potential neuroprotective effects on the CNS. Because ProteoSys...
...Remy Luthringer, who suggested testing the neuroprotective properties of the fragment in models of PD. ProteoSys...
BioCentury | Oct 6, 2008
Company News

bioMerieux, ProteoSys deal

...to IP covering the biomarker annexin A3 (ANXA3) to develop a diagnostic for prostate cancer. ProteoSys...
...upfront payment and is eligible for milestones and royalties. bioMerieux S.A. (Euronext:BIM), Marcy l'Etoile, France ProteoSys...
BioCentury | Feb 11, 2002
Politics, Policy & Law

German proteome consortium

...AG (Munich); Lion bioscience AG (NMarkt:LIO; LEON, Heidelberg); MTM Laboratories AG (Heidelberg); Nanotype GmbH (Graefelfing); ProteoSys AG...
Items per page:
1 - 4 of 4
BioCentury | Feb 4, 2013
Clinical News

Pirenzepine: Development discontinued

...tolerability of ACI-91 was rated as "good" in most patients. AC Immune in-licensed ACI-91 from ProteoSys...
...of crenezumab to treat AD are expected in 2014. AC Immune S.A. , Lausanne, Switzerland ProteoSys AG...
BioCentury | Aug 20, 2012
Emerging Company Profile

Mind-NRG: New neuroprotection

...that are involved in cognition and memory. In 2005, researchers at biomarker company ProteoSys AG (now ProteoSys...
...domain of the protein's beta-1 isoform - had potential neuroprotective effects on the CNS. Because ProteoSys...
...Remy Luthringer, who suggested testing the neuroprotective properties of the fragment in models of PD. ProteoSys...
BioCentury | Oct 6, 2008
Company News

bioMerieux, ProteoSys deal

...to IP covering the biomarker annexin A3 (ANXA3) to develop a diagnostic for prostate cancer. ProteoSys...
...upfront payment and is eligible for milestones and royalties. bioMerieux S.A. (Euronext:BIM), Marcy l'Etoile, France ProteoSys...
BioCentury | Feb 11, 2002
Politics, Policy & Law

German proteome consortium

...AG (Munich); Lion bioscience AG (NMarkt:LIO; LEON, Heidelberg); MTM Laboratories AG (Heidelberg); Nanotype GmbH (Graefelfing); ProteoSys AG...
Items per page:
1 - 4 of 4